Literature DB >> 15706439

Somatostatin, somatostatin receptors, and pancreatic cancer.

Min Li1, William E Fisher, Hee Joon Kim, Xiaoping Wang, Charles F Brunicardi, Changyi Chen, Qizhi Yao.   

Abstract

Somatostatin may play an important role in the regulation of cancer growth including pancreatic cancer by interaction with somatostatin receptors (SSTRs) on the cell surface. Five SSTRs were cloned, and the function of these SSTRs is addressed in this review. SSTR-2, SSTR-5, and SSTR-1 are thought to play major roles in inhibiting pancreatic cancer growth both in vitro and in vivo. SSTR-3 may be involved in mediating apoptosis, but the role of SSTR-4 is not clear. In most pancreatic cancers, functional SSTRs are absent. Reintroduction of SSTR genes has been shown to inhibit pancreatic cancer growth in cell cultures and animal models.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15706439     DOI: 10.1007/s00268-004-7814-5

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  40 in total

Review 1.  Pancreatic carcinoma.

Authors:  A L Warshaw; C Fernández-del Castillo
Journal:  N Engl J Med       Date:  1992-02-13       Impact factor: 91.245

2.  Somatostatin receptors in normal and tumoral tissue.

Authors:  J C Reubi; S W Lamberts; R Maurer
Journal:  Horm Res       Date:  1988

3.  Expression of somatostatin receptor subtype 1-5 genes in human pancreatic cancer.

Authors:  W E Fisher; T A Doran; P Muscarella; L G Boros; E C Ellison; W J Schirmer
Journal:  J Natl Cancer Inst       Date:  1998-02-18       Impact factor: 13.506

4.  Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia.

Authors:  M Fekete; T W Redding; A M Comaru-Schally; J E Pontes; R W Connelly; G Srkalovic; A V Schally
Journal:  Prostate       Date:  1989       Impact factor: 4.104

5.  Cancer statistics, 1998.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1998 Jan-Feb       Impact factor: 508.702

6.  The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors.

Authors:  C H van Eijck; S W Lamberts; L C Lemaire; H Jeekel; F T Bosman; J C Reubi; H A Bruining; E P Krenning
Journal:  Ann Surg       Date:  1996-08       Impact factor: 12.969

7.  Expression of the somatostatin receptor subtype-2 gene predicts response of human pancreatic cancer to octreotide.

Authors:  W E Fisher; P Muscarella; T M O'Dorisio; M S O'Dorisio; J A Kim; T A Doran; C L Sabourin; W J Schirmer
Journal:  Surgery       Date:  1996-08       Impact factor: 3.982

8.  Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion.

Authors:  Maria Chiara Zatelli; Daniela Piccin; Federico Tagliati; Maria Rosaria Ambrosio; Angelo Margutti; Roberto Padovani; Massimo Scanarini; Michael D Culler; Ettore C degli Uberti
Journal:  J Clin Endocrinol Metab       Date:  2003-06       Impact factor: 5.958

9.  Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study.

Authors:  L Canobbio; F Boccardo; D Cannata; P Gallotti; R Epis
Journal:  Cancer       Date:  1992-02-01       Impact factor: 6.860

Review 10.  Angiogenesis and antiangiogenic strategies in pancreatic cancer.

Authors:  William E Fisher; David H Berger
Journal:  Int J Gastrointest Cancer       Date:  2003
View more
  6 in total

1.  The role of chemotherapy and/or octreotide in patients with metastatic gastroenteropancreatic and hepatobiliary neuroendocrine carcinoma.

Authors:  Suk-Young Lee; Yoon Ji Choi; Won Jin Chang; Sang Won Shin; Yeul Hong Kim; Seung Tae Kim
Journal:  J Gastrointest Oncol       Date:  2014-12

2.  Chemo-hormone therapy of non-well-differentiated endocrine tumours from different anatomic sites with cisplatinum, etoposide and slow release lanreotide formulation.

Authors:  P Correale; A Sciandivasci; C Intrivici; A Pascucci; M T Del Vecchio; S Marsili; V Savelli; L Voltolini; M Di Bisceglie; A Guarnieri; G Gotti; G Francini
Journal:  Br J Cancer       Date:  2007-04-17       Impact factor: 7.640

3.  Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells.

Authors:  Luc Gailhouste; Lee Chuen Liew; Izuho Hatada; Hitoshi Nakagama; Takahiro Ochiya
Journal:  Cell Death Dis       Date:  2018-05-01       Impact factor: 8.469

4.  The human brain somatostatin interactome: SST binds selectively to P-type family ATPases.

Authors:  Michael Solarski; Declan Williams; Mohadeseh Mehrabian; Hansen Wang; Holger Wille; Gerold Schmitt-Ulms
Journal:  PLoS One       Date:  2019-05-28       Impact factor: 3.240

5.  Somatostatin Receptor 2: A Potential Predictive Biomarker for Immune Checkpoint Inhibitor Treatment.

Authors:  Aoyun Wang; Yixiao Yuan; Han Chu; Yixing Gao; Zheng Jin; Qingzhu Jia; Bo Zhu
Journal:  Pathol Oncol Res       Date:  2022-02-21       Impact factor: 3.201

Review 6.  Immunomodulatory Role of Neuropeptides in the Cornea.

Authors:  Sudan Puri; Brendan M Kenyon; Pedram Hamrah
Journal:  Biomedicines       Date:  2022-08-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.